UMM Institutional Repository

STUDI PENGGUNAAN NEUROPROTEKTAN TERHADAP PASIEN STROKE ISKEMIK DI INSTALASI RAWAT INAP (Penelitian Dilakukan di RSUD dr. Abdoer Rahem Situbondo)

Alfiyah, Rif’atul (2018) STUDI PENGGUNAAN NEUROPROTEKTAN TERHADAP PASIEN STROKE ISKEMIK DI INSTALASI RAWAT INAP (Penelitian Dilakukan di RSUD dr. Abdoer Rahem Situbondo). Undergraduate (S1) thesis, University of Muhammadiyah Malang.

[img]
Preview
Text
PENDAHULUAN.pdf

Download (3MB) | Preview
[img]
Preview
Text
BAB I.pdf

Download (1MB) | Preview
[img]
Preview
Text
BAB II.pdf

Download (9MB) | Preview
[img]
Preview
Text
BAB III.pdf

Download (545kB) | Preview
[img]
Preview
Text
BAB IV.pdf

Download (712kB) | Preview
[img]
Preview
Text
BAB V.pdf

Download (2MB) | Preview
[img] Text
BAB VI.pdf
Restricted to Registered users only

Download (2MB)
[img] Text
BAB VII.pdf
Restricted to Registered users only

Download (384kB)
[img] Text
LAMPIRAN.pdf
Restricted to Registered users only

Download (21MB)

Abstract

Background: Stroke is a sudden attack on a focal neurological deficit that lasts for at least 24 hours and occurs due to blood vessel disorders. Ischemic stroke is the most common type of stroke that occurs 88%. The goal of acute stroke treatment are to reduce the ongoing neurologic injury and decrease mortality and long-term disability. Neuroprotectan is one of therapy that intended to reduce the occurrence of cell damage due to impaired blood flow to supply oxygen. Objectives: The study aims to determine patterns of neuroprotectan utilization in patient with ischemic stroke and to examine the relationship neuroprotectan therapy related to the dose, route of administration, frequency of administration, and timing of administration associated with clinical data at the Hospital of Dr. Abdoer Rahem Situbondo. Methods: The study is a retrospective observational with consecutive sampling method in ischemic stroke patients from September to december 2017. Result & Conclusion: The study shows single neuroprotectant use of 6 patients (22%) and combination of 21 patients (78%). The widely use single neuroprotectant is citicoline (2x250 mg) IV in 2 patients (33%). The most commonly use combination neuroprotectant is citicoline (2x500 mg) IV with piracetam (3x1 g) IV of 18 patients (86%). The IV cycling pattern of citicoline (2x250mg) IV to citicoline (2x250mg) IV with piracetam (3x1 g) IV to piracetam (3x1 g) IV of 1 patient (50%), and the use of piracetam (3x3 g) IV to citicoline (2x250 mg) IV with piracetam (3x3 g) as much as 1 patient (50%).

Item Type: Thesis (Undergraduate (S1))
Student ID: 201410410311117
Keywords: Neuroprotectan, citicoline, Piracetam, Ischemic Strok
Subjects: R Medicine > RZ Other systems of medicine
Divisions: Faculty of Health Science > Department of Pharmacy (48201)
Depositing User: Nurhadin Nurhadin
Date Deposited: 12 Dec 2018 01:15
Last Modified: 12 Dec 2018 01:15
URI : http://eprints.umm.ac.id/id/eprint/41823

Actions (login required)

View Item View Item
UMM Official

© 2008 UMM Library. All Rights Reserved.
Jl. Raya Tlogomas No 246 Malang East Java Indonesia - Phone +62341464318 ext. 150, 151 - Fax +62341464101
E-Mail : infopus[at]umm.ac.id - Website : http://lib.umm.ac.id - Online Catalog : http://laser.umm.ac.id - Repository : http://eprints.umm.ac.id

Web Analytics

UMM Institutional Repository is powered by :
EPrints Logo